Supplemental Figure S2 from KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine
Year: 2023
Type: supplementary-materials
Abstract: A, cell viability after treatment with decitabine (AUC, x-axis) was plotted against the doubling time for each cell line (y-axis) as measured over nine days in 384-well plates at each cell line's optimized density. B, cell viability was measured after treatment with decitabine for nine days in four KRAS-mutant pancreatic cell lines. Data are representative of two independent experiments (14 replicates, mean {plus minus} SD). C, cell viability was measured after treatment with decitabine for nine days in KRAS-mutant (purple) or KRAS¬¬¬-wild type colon (gray) cancer cell lines. Data are representative of two independent experiments. Data are representative of two independent experiments (14 replicates, mean {plus minus} SD).
Authors: Michelle L. Stewart, Pablo Tamayo, Andrew J. Wilson, Stephanie Wang, Yun Min Chang, Jong W. Kim, Dineo Khabele, Alykhan F. Shamji, Stuart L. Schreiber
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362291652